The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets.
about
Peripherally Induced Regulatory T Cells: Recruited Protectors of the Central Nervous System against Autoimmune Neuroinflammation.The Hypoxia-Adenosine Link during Inflammation.Purinergic signaling during intestinal inflammation.Understanding the Holobiont: How Microbial Metabolites Affect Human Health and Shape the Immune System.What Else Can CD39 Tell Us?Multifaceted Effects of Extracellular Adenosine Triphosphate and Adenosine in the Tumor-Host Interaction and Therapeutic Perspectives.Targeting immunosuppressive adenosine in cancer.Prognostic and clinicopathological significance of ubiquitin-specific protease 22 overexpression in cancers: evidence from a meta-analysis.Soluble CD73 as biomarker in patients with metastatic melanoma patients treated with nivolumab.Characterization of ecto-nucleotidases in human oviducts with an improved approach simultaneously identifying protein expression and in situ enzyme activity.Informatics for cancer immunotherapy.Extracellular Adenosine Stimulates Vacuolar ATPase-Dependent Proton Secretion in Medullary Intercalated Cells.Clinical significance of CD73 in triple-negative breast cancer: multiplex analysis of a phase III clinical trial.Critical Interactions between Immunogenic Cancer Cell Death, Oncolytic Viruses, and the Immune System Define the Rational Design of Combination Immunotherapies.Ectonucleotidase CD39 expression in regional metastases in head and neck cancer.CD73 expression in lymph node metastases in patients with head and neck cancer.Metformin-induced reduction of CD39 and CD73 blocks myeloid-derived suppressor cell activity in patients with ovarian cancer.CD73-A2a adenosine receptor axis promotes innate B cell antibody responses to pneumococcal polysaccharide vaccination.Identification of allosteric inhibitors of the ecto-5'-nucleotidase (CD73) targeting the dimer interface.Extracellular 5'-nucleotidase (CD73) promotes human breast cancer cells growth through AKT/GSK-3β/β-catenin/cyclinD1 signaling pathway.The Hypoxia-Adenosine Link during Intestinal Inflammation.New Insights into the Immunobiology of Mononuclear Phagocytic Cells and Their Relevance to the Pathogenesis of Cardiovascular Diseases.Evaluation of WO2017098421: GSK's benzothiazine compounds as CD73 inhibitor filings.Accomplices of the Hypoxic Tumor Microenvironment Compromising Antitumor Immunity: Adenosine, Lactate, Acidosis, Vascular Endothelial Growth Factor, Potassium Ions, and Phosphatidylserine.The P2X7 Receptor in Inflammatory Diseases: Angel or Demon?Ectonucleotidase inhibitors: a patent review (2011-2016).Targeting the Adenosinergic Axis in Chronic Lymphocytic Leukemia: A Way to Disrupt the Tumor Niche?T-Cell Dysfunction in Glioblastoma: Applying a New Framework.A defect in KCa3.1 channel activity limits the ability of CD8+ T cells from cancer patients to infiltrate an adenosine-rich microenvironment.Mesenchymal Stromal Cells: What Is the Mechanism in Acute Graft-Versus-Host Disease?CD39 and immune regulation in a chronic helminth infection: The puzzling case of Mansonella ozzardi.Introduction to checkpoint inhibitors and cancer immunotherapy.Recent advances in CD8+ regulatory T cell research.Tumor immunotherapy: New aspects of natural killer cells.Controlling the Immune Suppressor: Transcription Factors and MicroRNAs Regulating CD73/NT5E.The Role of Extracellular Adenosine Generation in the Development of Autoimmune Diseases.How many diseases is triple negative breast cancer: the protagonism of the immune microenvironment.Targeting adenosine for cancer immunotherapy.Purinergic Ligands as Potential Therapeutic Tools for the Treatment of Inflammation-Related Intestinal Diseases.Tumor Necrosis Factor α and Regulatory T Cells in Oncoimmunology.
P2860
Q33650505-83001EBD-5D8F-4DB9-A369-36560DB2A8DCQ38644137-2B09804D-9A45-42DA-ACAE-B14A636FA5FCQ39331824-8B98AF32-F14D-4F12-8984-FEDDCEB6DB01Q39381331-E3165A02-6259-4AFC-A4F0-1F096AA61DDDQ39424529-BB0F0AE9-5ACE-4279-A113-58DB23CC2E0CQ46026307-2E40ED36-D1BB-42A5-B340-318E77A6DA5FQ46140918-DFA4A608-A6C6-48C7-9972-F5CAD7ACFD7CQ47108513-7CD94012-6938-459D-A95F-68F0F54C7AE2Q47131425-D43F5948-1AB6-447B-A917-94E6A022EBF0Q47259226-C3504226-7BD8-44E3-A52E-8B7432AAAC89Q47290509-696D2D9E-E2F7-4B3A-98DF-5FE593EEF891Q47313422-9D2FFEC6-4730-4D31-A028-B16F0296AE5AQ47395423-D7448F02-D8D6-4E08-9051-547FE442C416Q47557087-6A11C9D3-317C-401D-84E7-A1EBBE616314Q47573193-8ABFAFA6-D7FF-4BC9-ADE7-E9C5A241BE8AQ47630700-3627A3F4-0F5F-4597-AFA9-87F131F74317Q47640229-05520A72-684C-42B5-9853-37B7FAB6E415Q48149663-4807F841-70BC-4CA8-80C2-3AA62755BF01Q48150041-9625DEE6-6DF3-4616-80C9-55432DFE45C3Q48164127-0402D08C-B83C-4820-B229-B6D27ABD912DQ48191363-209D3108-1D6D-4FB5-A93D-E1F661D4F218Q49531175-EE740023-947A-45F9-AF33-3618E1E2217CQ49791703-254C0307-8C3E-4977-A656-FC7821F17C65Q50042918-8774DF84-39A3-438F-B382-6589CB70E2ECQ50202418-81A5187B-274E-46F7-B298-8F18175D3673Q50224587-7B780DD2-C400-46A2-A24B-71EB4C54EDECQ52323624-B71FAA3E-4220-4B9F-BB6E-C76943F023FDQ52625023-618742C4-6566-4C7A-BD71-B49D11D430BEQ52716939-C2BE2BFB-4CDE-4AD2-9514-F75BC0F604ADQ52763883-DA267E50-4500-4F0E-BE6F-BF97331ED3AFQ54262170-EBBE5647-B981-40AF-ABAA-2E8C2CED40FEQ54657348-4653CEDD-8FCC-436A-BE9C-AD065BC74249Q55078286-DF9DEE3E-2D70-4001-94C3-11610523F7BBQ55107050-8E2B9824-9FDA-4C50-9428-592760837634Q55251496-9143D9AD-F1A9-4101-8BA9-1321C3281DB5Q55261560-80505B11-8EBB-40BC-8182-9439F94E7CA4Q55316580-6BEC160D-0E90-4EED-969B-804C608925DAQ55330380-7D54DCF0-ECB3-42FB-BF0C-28BCD4356A31Q55340359-9B383043-489A-46D1-A805-9ACF46C9FC7FQ55386131-36844E76-4A10-47B9-B9A8-BB437AB214B8
P2860
The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets.
@en
The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets.
@nl
type
label
The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets.
@en
The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets.
@nl
prefLabel
The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets.
@en
The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets.
@nl
P2093
P2860
P356
P1476
The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets.
@en
P2093
Bertrand Allard
John Stagg
Maria Serena Longhi
Simon C Robson
P2860
P304
P356
10.1111/IMR.12528
P577
2017-03-01T00:00:00Z